ERBB2 and breast carcinoma: Trastuzumab, in combination with chemotherapy, achieves pCR rates of 29%-40%.9,12,13 In 2013, pertuzumab, another monoclonal antibody targeting HER2, received approval for the treatment of locally advanced HER2+ breast cancer in combination with trastuzumab and chemotherapy.